<DOC>
	<DOCNO>NCT01165008</DOCNO>
	<brief_summary>To investigate effect interleukin-1 ( IL-1 ) block agent , anakinra , patient treatment-resistant inflammatory myopathy . Patients method : Fifteen patient refractory polymyositis ( PM ) , dermatomyositis ( DM ) , inclusion body myositis ( IBM ) treat 100 mg anakinra subcutaneously per day 12 month . Outcome measure include myositis disease activity score improvement define accord The International Myositis Assessment Clinical Studies Group ( IMACS ) muscle performance functional index myositis ( FI ) . In addition repeat muscle biopsy perform</brief_summary>
	<brief_title>Anakinra Myositis</brief_title>
	<detailed_description />
	<mesh_term>Dermatomyositis</mesh_term>
	<mesh_term>Myositis</mesh_term>
	<mesh_term>Polymyositis</mesh_term>
	<mesh_term>Myositis , Inclusion Body</mesh_term>
	<mesh_term>Interleukin 1 Receptor Antagonist Protein</mesh_term>
	<criteria>Men woman age 18 80 year diagnosis PM , DM IBM base Peter Bohan 's Grigg 's criterion . All patient capable give informed consent . Other inclusion criterion muscle strength and/or function reduce least 20 % predict value measure functional index ( FI ) [ 4547 ] failure respond treatment highdose glucocorticoid ( 0.75 mg/kg/day least one month ) combination azathioprine and/or methotrexate least two month . serious infection hepatitis , pneumonia , pyelonephritis previous 3 month ; history opportunistic infection tuberculosis , drug resistant atypical mycobacterium , active pneumocystis carinii , active cytomegalovirus infection ; document HIV infection ; alcoholism , alcoholic liver disease chronic liver disease ; chest xray suggestive active tuberculosis ; pregnant , nursing mother patient plan pregnancy within one half year enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2005</verification_date>
</DOC>